Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2014 | Pages:
464 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Neuropathic Pain - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Neuropathic Pain - Pipeline Review, H2 2014', provides an overview of the Neuropathic Pain's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Neuropathic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuropathic Pain and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Neuropathic Pain - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuropathic Pain and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuropathic Pain pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Neuropathic Pain pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 Introduction 7 Neuropathic Pain Overview 8 Therapeutics Development 9 Neuropathic Pain - Therapeutics under Development by Companies 11 Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes 21 Neuropathic Pain - Pipeline Products Glance 23 Neuropathic Pain - Products under Development by Companies 27 Neuropathic Pain - Products under Investigation by Universities/Institutes 39 Neuropathic Pain - Companies Involved in Therapeutics Development 41 Neuropathic Pain - Therapeutics Assessment 143 Drug Profiles 157 Neuropathic Pain - Recent Pipeline Updates 395 Neuropathic Pain - Dormant Projects 428 Neuropathic Pain - Discontinued Products 432 Neuropathic Pain - Product Development Milestones 434 Appendix 441
List of Tables Number of Products under Development for Neuropathic Pain, H2 2014 31 Number of Products under Development for Neuropathic Pain - Comparative Analysis, H2 2014 32 Number of Products under Development by Companies, H2 2014 34 Number of Products under Development by Companies, H2 2014 (Contd..1) 35 Number of Products under Development by Companies, H2 2014 (Contd..2) 36 Number of Products under Development by Companies, H2 2014 (Contd..3) 37 Number of Products under Development by Companies, H2 2014 (Contd..4) 38 Number of Products under Development by Companies, H2 2014 (Contd..5) 39 Number of Products under Development by Companies, H2 2014 (Contd..6) 40 Number of Products under Development by Companies, H2 2014 (Contd..7) 41 Number of Products under Development by Companies, H2 2014 (Contd..8) 42 Number of Products under Investigation by Universities/Institutes, H2 2014 44 Comparative Analysis by Late Stage Development, H2 2014 45 Comparative Analysis by Clinical Stage Development, H2 2014 46 Comparative Analysis by Early Stage Development, H2 2014 47 Comparative Analysis by Unknown Stage Development, H2 2014 48 Products under Development by Companies, H2 2014 49 Products under Development by Companies, H2 2014 (Contd..1) 50 Products under Development by Companies, H2 2014 (Contd..2) 51 Products under Development by Companies, H2 2014 (Contd..3) 52 Products under Development by Companies, H2 2014 (Contd..4) 53 Products under Development by Companies, H2 2014 (Contd..5) 54 Products under Development by Companies, H2 2014 (Contd..6) 55 Products under Development by Companies, H2 2014 (Contd..7) 56 Products under Development by Companies, H2 2014 (Contd..8) 57 Products under Development by Companies, H2 2014 (Contd..9) 58 Products under Development by Companies, H2 2014 (Contd..10) 59 Products under Development by Companies, H2 2014 (Contd..11) 60 Products under Investigation by Universities/Institutes, H2 2014 61 Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 62 Neuropathic Pain - Pipeline by AbbVie Inc., H2 2014 63 Neuropathic Pain - Pipeline by Acorda Therapeutics, Inc., H2 2014 64 Neuropathic Pain - Pipeline by Advinus Therapeutics Ltd., H2 2014 65 Neuropathic Pain - Pipeline by Adynxx, Inc., H2 2014 66 Neuropathic Pain - Pipeline by Affectis Pharmaceuticals AG, H2 2014 67 Neuropathic Pain - Pipeline by Amura Holdings Ltd., H2 2014 68 Neuropathic Pain - Pipeline by AnaBios Corporation, H2 2014 69 Neuropathic Pain - Pipeline by Anavex Life Sciences Corp., H2 2014 70 Neuropathic Pain - Pipeline by AngioChem Inc., H2 2014 71 Neuropathic Pain - Pipeline by Asahi Kasei Pharma Corp., H2 2014 72 Neuropathic Pain - Pipeline by Astellas Pharma Inc., H2 2014 73 Neuropathic Pain - Pipeline by AstraZeneca PLC, H2 2014 74 Neuropathic Pain - Pipeline by Auspex Pharmaceuticals, Inc., H2 2014 75 Neuropathic Pain - Pipeline by Avanir Pharmaceuticals, Inc., H2 2014 76 Neuropathic Pain - Pipeline by BBB Therapeutics B.V., H2 2014 77 Neuropathic Pain - Pipeline by BCN Peptides, S.A., H2 2014 78 Neuropathic Pain - Pipeline by Benitec Biopharma Limited, H2 2014 79 Neuropathic Pain - Pipeline by Bial - Portela & Ca, S.A., H2 2014 80 Neuropathic Pain - Pipeline by Biogen Idec Inc., H2 2014 81 Neuropathic Pain - Pipeline by BioLineRx, Ltd., H2 2014 82 Neuropathic Pain - Pipeline by Biomar Microbial Technologies, H2 2014 83 Neuropathic Pain - Pipeline by Bionomics Limited, H2 2014 84 Neuropathic Pain - Pipeline by Bristol-Myers Squibb Company, H2 2014 85 Neuropathic Pain - Pipeline by Cara Therapeutics, Inc., H2 2014 86 Neuropathic Pain - Pipeline by Cavion LLC, H2 2014 87 Neuropathic Pain - Pipeline by Cerecor Inc., H2 2014 88 Neuropathic Pain - Pipeline by CLL Pharma, H2 2014 89 Neuropathic Pain - Pipeline by Colby Pharmaceutical Company, H2 2014 90 Neuropathic Pain - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 91 Neuropathic Pain - Pipeline by Convergence Pharmaceuticals Ltd., H2 2014 92 Neuropathic Pain - Pipeline by Creabilis SA, H2 2014 93 Neuropathic Pain - Pipeline by Cytogel Pharma, LLC, H2 2014 94 Neuropathic Pain - Pipeline by DermaXon, LLC, H2 2014 95 Neuropathic Pain - Pipeline by Eisai Co., Ltd., H2 2014 96 Neuropathic Pain - Pipeline by Endece, LLC, H2 2014 97 Neuropathic Pain - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 98 Neuropathic Pain - Pipeline by Evotec AG, H2 2014 99 Neuropathic Pain - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 100 Neuropathic Pain - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2014 101 Neuropathic Pain - Pipeline by Glialogix, Inc., H2 2014 102 Neuropathic Pain - Pipeline by Grunenthal GmbH, H2 2014 103 Neuropathic Pain - Pipeline by Hydra Biosciences, Inc., H2 2014 104 Neuropathic Pain - Pipeline by Integral Molecular, Inc., H2 2014 105 Neuropathic Pain - Pipeline by IntelGenx Corp., H2 2014 106 Neuropathic Pain - Pipeline by Intellipharmaceutics International Inc., H2 2014 107 Neuropathic Pain - Pipeline by Johnson & Johnson, H2 2014 108 Neuropathic Pain - Pipeline by Kareus Therapeutics, SA, H2 2014 109 Neuropathic Pain - Pipeline by Kineta, Inc., H2 2014 110 Neuropathic Pain - Pipeline by Knopp Biosciences LLC, H2 2014 111 Neuropathic Pain - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2014 112 Neuropathic Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2014 113 Neuropathic Pain - Pipeline by LEO Pharma A/S, H2 2014 114 Neuropathic Pain - Pipeline by Lipopharma Therapeutics SL, H2 2014 115 Neuropathic Pain - Pipeline by Lohocla Research Corporation, H2 2014 116 Neuropathic Pain - Pipeline by Lpath, Inc., H2 2014 117 Neuropathic Pain - Pipeline by Maruho Co., Ltd., H2 2014 118 Neuropathic Pain - Pipeline by Medisyn Technologies, Inc., H2 2014 119 Neuropathic Pain - Pipeline by Medivir AB, H2 2014 120 Neuropathic Pain - Pipeline by Mertiva AB, H2 2014 121 Neuropathic Pain - Pipeline by Nanomerics Ltd, H2 2014 122 Neuropathic Pain - Pipeline by Naurex, Inc., H2 2014 123 Neuropathic Pain - Pipeline by Nektar Therapeutics, H2 2014 124 Neuropathic Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2014 125 Neuropathic Pain - Pipeline by Neurodyn Inc., H2 2014 126 Neuropathic Pain - Pipeline by NeurOp, Inc, H2 2014 127 Neuropathic Pain - Pipeline by Neurotune AG, H2 2014 128 Neuropathic Pain - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 129 Neuropathic Pain - Pipeline by Nippon Chemiphar Co., Ltd., H2 2014 130 Neuropathic Pain - Pipeline by NsGene A/S, H2 2014 131 Neuropathic Pain - Pipeline by Nuvo Research Inc., H2 2014 132 Neuropathic Pain - Pipeline by Pharmaleads , H2 2014 133 Neuropathic Pain - Pipeline by PharmEste, H2 2014 134 Neuropathic Pain - Pipeline by Pluristem Therapeutics Inc., H2 2014 135 Neuropathic Pain - Pipeline by Quark Pharmaceuticals, Inc., H2 2014 136 Neuropathic Pain - Pipeline by RAPID Pharmaceuticals AG, H2 2014 137 Neuropathic Pain - Pipeline by RaQualia Pharma Inc., H2 2014 138 Neuropathic Pain - Pipeline by Re-Pharm Limited, H2 2014 139 Neuropathic Pain - Pipeline by Recro Pharma, Inc., H2 2014 140 Neuropathic Pain - Pipeline by Revance Therapeutics, Inc., H2 2014 141 Neuropathic Pain - Pipeline by Rottapharm SpA, H2 2014 142 Neuropathic Pain - Pipeline by Sangamo BioSciences, Inc., H2 2014 143 Neuropathic Pain - Pipeline by Saniona AB, H2 2014 144 Neuropathic Pain - Pipeline by Shionogi & Co., Ltd., H2 2014 145 Neuropathic Pain - Pipeline by Sigma-Tau S.p.A., H2 2014 146 Neuropathic Pain - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 147 Neuropathic Pain - Pipeline by Snowdon Inc., H2 2014 148 Neuropathic Pain - Pipeline by Spinifex Pharmaceuticals Pty Limited, H2 2014 149 Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H2 2014 150 Neuropathic Pain - Pipeline by Suven Life Sciences Ltd., H2 2014 151 Neuropathic Pain - Pipeline by Syntrix Biosystems, Inc., H2 2014 152 Neuropathic Pain - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 153 Neuropathic Pain - Pipeline by Targacept, Inc., H2 2014 154 Neuropathic Pain - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 155 Neuropathic Pain - Pipeline by Torrent Pharmaceuticals Limited, H2 2014 156 Neuropathic Pain - Pipeline by Trevena, Inc., H2 2014 157 Neuropathic Pain - Pipeline by Trigemina, Inc., H2 2014 158 Neuropathic Pain - Pipeline by Vernalis plc, H2 2014 159 Neuropathic Pain - Pipeline by Vichem Chemie Research Ltd., H2 2014 160 Neuropathic Pain - Pipeline by Virobay Inc., H2 2014 161 Neuropathic Pain - Pipeline by VistaGen Therapeutics , Inc., H2 2014 162 Neuropathic Pain - Pipeline by WEX Pharmaceuticals Inc., H2 2014 163 Neuropathic Pain - Pipeline by Yungjin Pharm Ind. Co., Ltd., H2 2014 164 Assessment by Monotherapy Products, H2 2014 165 Assessment by Combination Products, H2 2014 166 Number of Products by Stage and Target, H2 2014 168 Number of Products by Stage and Mechanism of Action, H2 2014 171 Number of Products by Stage and Route of Administration, H2 2014 176 Number of Products by Stage and Molecule Type, H2 2014 178 Neuropathic Pain Therapeutics - Recent Pipeline Updates, H2 2014 417 Neuropathic Pain - Dormant Projects, H2 2014 450 Neuropathic Pain - Discontinued Products, H2 2014 454
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
